Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

被引：0
|
作者：
Safonov, Anton Mikhailovich
Bandlamudi, Chaitanya
Selenica, Pier
Marra, Antonio
Ferraro, Emanuela
Mandelker, Diana
Solit, David B.
Berger, Michael F.
Norton, Larry
Powell, Simon N.
Shen, Ronglai
Robson, Mark E.
Chandarlapaty, Sarat
Reis-Filho, Jorge S.
Razavi, Pedram
机构：
[1] Hosp Univ Penn, Philadelphia, PA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Milan, Italy
[4] Sloan Kettering Inst, Weill Cornell Med Coll, Kravis Ctr Mol Oncol, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
    Moukas, Stefanos Ioannis
    Kasimir-Bauer, Sabine
    Tewes, Mitra
    Kolberg, Hans-Christian
    Hoffmann, Oliver
    Kimmig, Rainer
    Keup, Corinna
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
    Stefanos Ioannis Moukas
    Sabine Kasimir-Bauer
    Mitra Tewes
    Hans-Christian Kolberg
    Oliver Hoffmann
    Rainer Kimmig
    Corinna Keup
    Scientific Reports, 13
  • [34] Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
    Chen, Fengquan
    Liu, Chunxi
    Zhang, Jian
    Xu, Wenfang
    Zhang, Yingjie
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (09) : 1241 - 1251
  • [35] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
  • [36] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [37] CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
    Zhou, Fiona H.
    Downton, Teesha
    Freelander, Allegra
    Hurwitz, Joshua
    Caldon, C. Elizabeth
    Lim, Elgene
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [38] Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
    Sobhani, Navid
    Fassl, Anne
    Mondani, Giuseppina
    Generali, Daniele
    Otto, Tobias
    CELLS, 2021, 10 (02) : 1 - 14
  • [39] Mechanisms of CDK4/6 inhibitor resistance in hormone receptor positive metastatic breast cancer: Single institution retrospective analysis
    Lee, Jin Sun
    Yost, Susan
    Cui, Yujie
    Frankel, Paul
    Li, Sierra Min
    Yuan, Yate-Ching
    Morse, Denise
    Wong-Toh, Judy
    Bosserman, Linda
    Mortimer, Joanne
    Yuan, Yuan
    CANCER RESEARCH, 2022, 82 (04)
  • [40] Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer
    Lim, Elgene
    Portman, Neil
    Alexandrou, Sarah
    Haupt, Susan
    Haupt, Ygal
    Caldon, Elizabeth
    CANCER RESEARCH, 2018, 78 (04)
12345